
Oscar Corli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9806709/publications.pdf

Version: 2024-02-01



OSCAR CORL

#	Article	IF	CITATIONS
1	Living systematic review to assess the analgesic undertreatment in cancer patients. Pain Practice, 2022, 22, 487-496.	0.9	19
2	Influence of Physical Activity on Pain, Depression and Quality of Life of Patients in Palliative Care: A Proof-of-Concept Study. Journal of Clinical Medicine, 2021, 10, 1012.	1.0	4
3	Use of preventive drugs during the last year of life in older adults with cancer or chronic progressive diseases. Pharmacoepidemiology and Drug Safety, 2021, 30, 1057-1065.	0.9	5
4	Efficacy and Safety of Peripherally Acting μ-Opioid Receptor Antagonist (PAMORAs) for the Management of Patients With Opioid-Induced Constipation: A Systematic Review. Cureus, 2021, 13, e16201.	0.2	13
5	Factors for Timely Identification of Possible Occurrence of Delirium in Palliative Care: A Prospective Observational Study. Advances in Therapy, 2021, 38, 4289-4303.	1.3	2
6	Pain and Frailty in Hospitalized Older Adults. Pain and Therapy, 2020, 9, 727-740.	1.5	22
7	Impact of Palliative Care in Evaluating and Relieving Symptoms in Patients with Advanced Cancer. Results from the DEMETRA Study. International Journal of Environmental Research and Public Health, 2020, 17, 8429.	1.2	5
8	Nutraceuticals and Exercise against Muscle Wasting during Cancer Cachexia. Cells, 2020, 9, 2536.	1.8	23
9	Clinical Care Conditions and Needs of Palliative Care Patients from Five Italian Regions: Preliminary Data of the DEMETRA Project. Healthcare (Switzerland), 2020, 8, 221.	1.0	8
10	The Complex Balance between Analgesic Efficacy, Change of Dose and Safety Profile Over Time, in Cancer Patients Treated with Opioids: Providing the Clinicians with an Evaluation Tool. Journal of Clinical Medicine, 2020, 9, 502.	1.0	2
11	Identification of genetic polymorphisms modulating nausea and vomiting in two series of opioid-treated cancer patients. Scientific Reports, 2020, 10, 542.	1.6	4
12	Systematic Review and Metaâ€Analysis on Neuropsychological Effects of Longâ€Term Use of Opioids in Patients With Chronic Noncancer Pain. Pain Practice, 2019, 19, 328-343.	0.9	32
13	Oral Prolongedâ€Release Oxycodoneâ€Naloxone: Analgesic Response, Safety Profile, and Factors Influencing the Response in Patients With Advanced Cancer. Pain Practice, 2019, 19, 633-643.	0.9	2
14	The Burden of Opioid Adverse Events and the Influence on Cancer Patients' Symptomatology. Journal of Pain and Symptom Management, 2019, 57, 899-908.e6.	0.6	17
15	Lack of Efficacy: When Opioids Do Not Achieve Analgesia from the Beginning of Treatment in Cancer Patients. Cancer Management and Research, 2019, Volume 11, 10337-10344.	0.9	3
16	Cannabis as a medicine. An update of the Italian reality. European Journal of Internal Medicine, 2019, 60, e9-e10.	1.0	5
17	Trends in the consumption of opioids for the treatment of severe pain in Europe, 1990–2016. European Journal of Pain, 2019, 23, 697-707.	1.4	86
18	Nonresponsiveness and Susceptibility of Opioid Side Effects Related to Cancer Patients' Clinical Characteristics: A Postâ€Hoc Analysis. Pain Practice, 2018, 18, 748-757.	0.9	12

OSCAR CORLI

#	Article	IF	CITATIONS
19	Including cannabinoids in the treatment of painful schwannomatosis. Brain and Behavior, 2018, 8, e01011.	1.0	1
20	Prevalence, characteristics and treatment of chronic pain in elderly patients hospitalized in internal medicine wards. European Journal of Internal Medicine, 2018, 55, 35-39.	1.0	24
21	A comparison between the administration of oral prolonged-release oxycodone-naloxonee and transdermal fentanyl in patients with moderate-to-severe cancer pain: a propensity score analysis. Journal of Pain Research, 2017, Volume 10, 2123-2133.	0.8	6
22	Factors influencing the analgesic response over time of the oxycodone-naloxone association in painful cancer patients: GREAT study Journal of Clinical Oncology, 2017, 35, 10089-10089.	0.8	0
23	Long-term efficacy and safety of oxycodone–naloxone prolonged release in geriatric patients with moderate-to-severe chronic noncancer pain: a 52-week open-label extension phase study. Drug Design, Development and Therapy, 2016, 10, 1515.	2.0	23
24	Good and Bad Responses to a Pain Therapy: How to Discriminate Between Them?. Journal of Clinical Oncology, 2016, 34, 3579-3579.	0.8	1
25	Prevalence of Neuropathic Pain in Cancer Patients: Pooled Estimates From a Systematic Review of Published Literature and Results From a Survey Conducted in 50 Italian Palliative Care Centers. Journal of Pain and Symptom Management, 2016, 51, 1091-1102.e4.	0.6	48
26	Non-clinical factors influencing pain intensity in cancer patients: Socio-cultural–economic status, awareness of disease and the relation with the oncologist. European Journal of Internal Medicine, 2016, 33, e18-e19.	1.0	4
27	Efficacy and tolerability of oral oxycodone and oxycodone/naloxone combination in opioid-naïve cancer patients: a propensity analysis. Drug Design, Development and Therapy, 2015, 9, 5863.	2.0	34
28	The stigma of low opioid prescription in the hospitalized multimorbid elderly in Italy. Internal and Emergency Medicine, 2015, 10, 305-313.	1.0	7
29	Reply to S. Mercadante et al. Journal of Clinical Oncology, 2015, 33, 2119-2120.	0.8	3
30	Prevalence of Breakthrough Cancer Pain: AÂSystematic Review and a Pooled Analysis of Published Literature. Journal of Pain and Symptom Management, 2014, 47, 57-76.	0.6	167
31	Quality of Cancer Pain Management: An Update of a Systematic Review of Undertreatment of Patients With Cancer. Journal of Clinical Oncology, 2014, 32, 4149-4154.	0.8	393
32	A New Focus on Breakthrough Cancer Pain: Commentary on Davies etÂal Journal of Pain and Symptom Management, 2013, 46, 618.	0.6	0
33	Quality for home palliative care: an Italian metropolitan multicentre JCI-certified model. BMJ Supportive and Palliative Care, 2012, 2, 57-62.	0.8	Ο
34	Response to letter by Mercadante. Pain, 2012, 153, 1771-1772.	2.0	0
35	An Exploratory Analysis on the Effectiveness of Four Strong Opioids in Patients with Cancer Pain. Pain Medicine, 2012, 13, 897-907.	0.9	22
36	Which domains should be included in a cancer pain classification system? Analyses of longitudinal data. Pain, 2012, 153, 696-703.	2.0	54

OSCAR CORLI

#	Article	IF	CITATIONS
37	Expert conference on cancer pain assessment and classificationthe need for international consensus: working proposals on international standards. BMJ Supportive and Palliative Care, 2011, 1, 281-287.	0.8	56
38	Epidemiology and Pattern of Care of Breakthrough Cancer Pain in a Longitudinal Sample of Cancer Patients. Clinical Journal of Pain, 2011, 27, 9-18.	0.8	86
39	Which variables are associated with pain intensity and treatment response in advanced cancer patients?— Implications for a future classification system for cancer pain. European Journal of Pain, 2011, 15, 320-327.	1.4	63
40	Quality for home palliative care: an Italian metropolitan multicentre JCI-certified model. BMJ Quality and Safety, 2011, 20, 592-598.	1.8	9
41	Effects of Transdermal Buprenorphine on Patients-reported Outcomes in Cancer Patients. Clinical Journal of Pain, 2009, 25, 671-682.	0.8	8
42	Pain in cancer. An outcome research project to evaluate the epidemiology, the quality and the effects of pain treatment in cancer patients. Health and Quality of Life Outcomes, 2006, 4, 7.	1.0	23
43	Effectiveness of levosulpiride versus metoclopramide for nausea and vomiting in advanced cancer patients: A double-blind, randomized, crossover study. Journal of Pain and Symptom Management, 1995, 10, 521-526.	0.6	28
44	A new method of food intake quantification: Application to the care of cancer patients. Journal of Pain and Symptom Management, 1992, 7, 12-17.	0.6	9